| 11/24/2015 | CVIG | Fitch puts Allergan on positive watch
|
| 11/23/2015 | CVIG | Moody’s reviews Allergan, Actavis, Forest
|
| 7/7/2014 | BKHYIG | S&P ups Forest Laboratories notes to BBB-
|
| 7/1/2014 | BKHYIG | Moody's lifts Forest Labs from junk
|
| 7/1/2014 | BKHYIG | Fitch rates Forest Labs BBB-; affirms Actavis
|
| 6/16/2014 | BKHYIG | S&P puts Forest Laboratories on positive watch
|
| 6/12/2014 | HYLM | Actavis gets needed consents to guarantee Forest Laboratories notes
|
| 6/9/2014 | HYLM | Actavis extends offers to guarantee Forest Lab notes for acquisition
|
| 2/19/2014 | HY | Market Commentary: Upsized D.R. Horton drive-by, Modular Space price in quiet market; firmer tone seen
|
| 2/18/2014 | BKIG | Actavis secures bridge loan for $25 billion acquisition of Forest Labs
|
| 2/18/2014 | BKHYIG | Moody's might upgrade Forest Labs
|
| 2/18/2014 | HY | Market Commentary: Post-holiday primary silent; Modular Space deal slates; takeover news boosts Forest Labs
|
| 1/28/2014 | HY | Market Commentary: Puma Energy, North Atlantic price, First Quantum up on swap; AK Steel, Texas Industries gain
|
| 1/28/2014 | BKHY | S&P assigns Forest Lab notes BB+
|
| 1/27/2014 | BKHY | Moody's rates Forest Lab notes Ba1
|
| 1/27/2014 | HY | Forest Laboratories plans to price $1.8 billion two-part bullet notes in Monday drive-by
|
| 1/27/2014 | HY | New Issue: Forest Laboratories prices $1.8 billion notes in bullet tranches
|
| 1/27/2014 | HY | Market Commentary: Junk primary revives as Forest Labs, Harland Clarke lead $2.7 billion pricing spree
|
| 1/21/2014 | BKHY | Forest Laboratories' net sales up, net income down for third quarter
|
| 1/8/2014 | BKHY | Forest gets $1.9 billion bridge loan commitment for Aptalis purchase
|
| 1/8/2014 | HY | Market Commentary: Icahn's giant three-parter prices, along with Sabra Health; new Parker bonds rise, MDC busy
|
| 12/9/2013 | HY | Market Commentary: Giant Sprint deal drives by, dominates primary; US Foods bonds jump on planned sale to Sysco
|
| 12/6/2013 | HY | Market Commentary: Upsized Ultra Petroleum, Abengoa deals pace busy session, cap $10.5 billion week
|
| 12/5/2013 | HY | Market Commentary: Forest, Altice drive-bys lead $4.9 billion day, biggest in two months; funds lose $142 million
|
| 12/5/2013 | HY | New Issue: Forest Laboratories upsizes to $1.2 billion, prices eight-year notes at par to yield 5%
|
| 12/4/2013 | HY | Forest Laboratories talks $1 billion notes due 2021 to yield 5%-51/4%
|
| 12/4/2013 | HY | Market Commentary: Reynolds leads drive-by parade, firms solidly; new Prestige Brand paper higher
|
| 12/4/2013 | HY | Market Commentary: Reynolds leads drive-by parade, firms solidly; new Prestige Brand paper higher
|
| 12/3/2013 | HY | Market Commentary: Prestige Brands prices; new Ally, Aircastle bonds busy; AK Steel up on trade ruling
|
| 12/3/2013 | HY | S&P: Forest Labs notes BB+
|
| 12/2/2013 | BK | Forest Labs amends facility to change consolidated EBITDA definition
|
| 12/2/2013 | HY | Forest Laboratories plans to price $1 billion bullet deal on Thursday
|
| 12/2/2013 | HY | Moody's assigns Forest Labs notes Ba1
|
| 12/2/2013 | HY | Market Commentary: Upsized Ally, Aircastle deals price, calendar builds, NII slips again; funds add $433 million
|
| 12/7/2012 | BK | Forest Laboratories seals $750 million five-year revolving commitments
|
| 4/12/2011 | LMPP | Forest Labs accepts $50 million of tendered Clinical Data convertibles
|
| 5/29/2008 | SP | New Issue: Barclays prices $1.5 million 9% reverse convertibles linked to Forest Laboratories
|
| 5/9/2008 | SP | Barclays to price 9% reverse convertibles linked to Forest Laboratories
|
| 3/28/2008 | SP | New Issue: Barclays prices $2 million 10% reverse convertibles linked to Forest Laboratories
|
| 3/25/2008 | SP | New Issue: JPMorgan prices $556,000 10% reverse exchangeables linked to Forest Laboratories
|
| 3/11/2008 | SP | Barclays to price 10% reverse convertibles linked to Forest Laboratories
|
| 2/26/2008 | SP | New Issue: Barclays prices $1.5 million 10% reverse convertibles linked to Forest Laboratories
|
| 1/28/2008 | SP | New Issue: ABN Amro prices $1.4 million 12% reverse exchangeables linked to Forest Laboratories
|
| 8/27/2007 | SP | New Issue: Eksportfinans prices $1.2 million 13% reverse convertibles linked to Forest Labs via Natixis
|
| 10/26/2006 | BT | RBC lowers target for Forest
|
| 10/23/2006 | BT | Forest at sector perform by RBC
|
| 10/23/2006 | BT | Market Commentary: Connetics gains 46% on merger; Replidyne falls 45%, Forest down 6%; Adeza loses 16%; Amgen off
|
| 10/18/2006 | BT | RBC ups Forest target
|
| 10/18/2006 | BT | Forest cut to hold by Jefferies
|
| 10/17/2006 | BT | Forest Laboratories reports increased revenues, sales of marketed brands
|
| 10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
| 8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
| 7/25/2006 | BT | Paion's phase 3 stroke trial on target for full enrollment
|
| 7/19/2006 | BT | Jefferies maintains Forest at buy
|
| 7/19/2006 | BT | Forest at sector perform rating by RBC
|
| 7/18/2006 | BT | Forest Laboratories reports net income of $200.60 million for first quarter of fiscal 2007
|
| 7/14/2006 | BT | Market Commentary: deCODE secures $30 million from stock sale; Micrus stock edges up following public stock offering
|
| 7/14/2006 | CV | Market Commentary: Ford slides as story sputters; GM weaker; deCODE Genetics widens; Teva steady despite loss to Forest
|
| 7/14/2006 | BT | Jefferies upgrades Forest Labs to buy
|
| 7/13/2006 | BT | Forest wins over generic on Lexapro patent
|
| 7/11/2006 | BT | Lundbeck, Forest Labs file Lexapro patent infringement suit against Caraco Pharmaceutical
|
| 6/28/2006 | BT | Market Commentary: Replidyne debut shaky but closes in the green; Indevus rises in face of spot sale; Depomed loses 3%
|
| 5/18/2006 | BT | Forest announces new share repurchase program
|
| 5/8/2006 | BT | Jefferies specialty pharmaceuticals report
|
| 4/26/2006 | BT | Jefferies keeps Forest Labs at hold
|
| 4/25/2006 | BT | Jefferies rates Forest at hold
|
| 4/17/2006 | BT | Forest Labs on hold by Jefferies
|
| 4/10/2006 | BT | Forest, Almirall to collaborate for new pulmonary disease therapy
|
| 3/30/2006 | BT | Citigroup reiterates Forest at buy
|
| 3/30/2006 | BT | Merrill maintains Forest at buy
|
| 3/28/2006 | BT | Citigroup reiterates Forest at buy
|
| 3/10/2006 | BT | Merrill keeps Forest Labs at buy
|
| 3/2/2006 | BT | Forest Laboratories receives patent term extension for Lexapro
|
| 2/23/2006 | BT | FDA to review Replidyne's, Forest Laboratories' NDA for oral antibiotic
|
| 2/13/2006 | BT | Forest Laboratories, Replidyne form licensing agreement for antibiotic
|
| 1/18/2006 | BT | Citigroup maintains Forest Labs at buy
|
| 1/18/2006 | BT | Forest Labs reiterated by Jefferies at hold
|
| 1/12/2006 | BT | Citigroup reiterates Forest Labs at buy
|
| 1/11/2006 | BT | Mylan licenses nebivolol to Forest, to receive $75 million and milestones
|
| 1/5/2006 | BT | Forest, Cypress to run third phase 3 trial of milnacipran for fibromyalgia
|
| 10/19/2005 | BT | Citigroup maintains forecasts for Forest Labs
|
| 10/19/2005 | BT | Jefferies lowers Forest Labs' price target, reiterates hold
|
| 10/14/2005 | BT | Forest Labs hold rating reiterated by Jefferies
|
| 9/29/2005 | BT | Forest initiated by Leerink Swann at market perform
|
| 9/29/2005 | BT | Forest Labs reiterated by Jefferies at hold
|
| 9/29/2005 | BT | Market Commentary: Genomic, Avalon sink after IPOs price at low end; Forest, Cypress dive; SkinMedica's IPO on deck
|
| 9/29/2005 | BT | Forest maintained by Smith Barney at buy
|
| 8/18/2005 | BT | Forest Laboratories at hold: Jefferies
|
| 7/25/2005 | BT | Market Commentary: Teva purchases Ivax, both higher; Endo Pharma climbs on possible sale of Ivax pain drug
|
| 7/20/2005 | BT | Forest Labs maintained by Jefferies at hold
|
| 7/15/2005 | BT | Forest Labs target price upped by Jefferies
|
| 6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
| 6/1/2005 | CV | New Issue: Morgan Stanley prices $24 million 7% Sparqs exchangeable for Forest Laboratories
|
